|| List of recent G Protein-related patents
|Oligosaccharide modification and labeling of proteins|
The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention..
|Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation|
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent.
|Il4/il13 binding repeat proteins and uses|
Il4/il13-binding proteins comprise binding domains, which inhibit il4/il13 binding to il4ralpha and common gamma chain complexes (type 1) and inhibit il4 binding to il4ralpha and il13ralpha1 complexes (type 2), and il13 binding to il13ralpha1 and/or il13ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.. .
|Compositions and methods for molecular biology|
The present invention provides materials and methods for the utilization of the specific interaction of replication termination sequences with their binding proteins in molecular biology applications.. .
|Detecting a high molecular weight substance|
Label complexes, lateral flow apparatus and methods of detecting a high molecular weight substance are shown and described. In one embodiment, the label complex includes an antispecies antibody and another antibody having sensitivity to both the antispecies antibody and to a control line capture agent, an antibody binding protein and a detectable component.
|Cross-linking compositions and related methods of isotope tagging of interacting proteins and analysis of protein interactions|
An isotope labeled asymmetric cross-linker is provided for the detection of cross-linked peptides. A cross-linking and mass spectrometry strategy, referred to as isotope tagging of interacting proteins (itip), improves the specificity of detecting cross-linked peptides and accurate identification of the interacting peptide sequences via the incorporation of isotopic signatures that are readily observed in the ms/ms spectrum.
|Methods and kits for detecting mastitis|
Methods and kits for determining if one or more animals have mastitis and for monitoring animals and the quality of the milk they produce are disclosed. Kits and test assays disclosed are used to determine the quantity of proteasomes and proteins thereof, the activity of proteasome enzymes, the quantity of proteasome bound and regulating proteins, and the quantity of ubiquinated protein.
|Inhibitors of extracellular proteases|
Provided is a plant derived extract including inhibitory activity against one or more extracellular proteases which degrade human tissue matrix. Moreover, the amount of inhibitory activity in an extract can be increased by stressing the plant prior to forming an extract.
|Treatment of cardiovascular disorders using the cell differentiation signaling protein nell1|
It has been identified in accordance with the present invention that nell1 is essential for normal cardiovascular development by promoting proper formation of the heart and blood vessels. The present invention therefore provides therapeutic methods for treating cardiovascular disorders by employing a nell1 protein or nucleic acid molecule..
|Il-1 binding proteins|
Proteins that bind il-1α and il-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing il-1-related disorders and for detecting il-1α and il-1β in cells, tissues, samples, and compositions.. .
|Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same|
The present invention provides new compounds of formula i, ii or iii, which have src homology-2 containing protein tyrosine phosphatase-1 (shp-1) agonist activity. Also provided are treatment methods using the compounds of formula i, ii or iii..
|Small molecule composite surfaces as inhibitors of protein-protein interactions|
A method of inhibiting a binding event between a target protein and a binding protein, comprising administering to a cell in vitro an effective amount of a non-naturally occurring bifunctional inhibitor molecule including (a) protein binding moiety, and (b) an effector region, wherein the protein binding moiety binds to a blocking protein, and wherein the effector region binds to the target protein in order to bind the target protein and the blocking protein and prevent access of the binding protein to the target protein. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
|Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens|
Methods for producing proteins and glycoproteins in pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an n-glycan or o-glycan and do not display at least one activity selected from a β-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins.
|Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer|
Provided are compositions, methods and kits for quantifying the expression and/or activity of mmp-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens.. .
|Brown adipocyte modification|
Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss.
|Method for manufacturing protein drug|
The present invention provides a method for manufacturing a virus-free protein drug, comprising (a) a filtration step of filtering a virus-containing protein solution through a small-pore size virus removal membrane to obtain a virus-free protein solution, the filtration step (a) comprising (q) a low-pressure filtration step of filtering the solution through the small-pore size virus removal membrane at a filtration pressure of 0.30 kgf/cm2 or lower to obtain the virus-free protein solution, wherein the solution prior to filtration in the low-pressure filtration step (q) has a ph (x) and a salt ionic strength (y (mm)) that satisfy the following equations 1 and 5: 0≦y≦150x−590 (equation 1) and 3.5≦x≦8.0 (equation 5) or the following equations 4 and 5: y=0 (equation 4) and 3.5≦x≦8.0 (equation 5).. .
|Systems and methods of detecting and demonstrating hair damage via evaluation of protein fragments|
Embodiments of a method for demonstrating type and/or source of hair damage comprises extracting protein fragments from a hair sample with an aqueous solution, testing the resulting protein fragments with the maldi-ms test, and then either comparing the results between a damaged sample and an undamaged sample or comparing the results between a damaged sample and a list of known marker protein fragments to identify the type and/or source of the damage.. .
|Method for isolating cell-type specific mrnas|
The invention provides methods for isolating cell-type specific mrnas by selectively isolating ribosomes or proteins that bind mrna in a cell type specific manner, and, thereby, the mrna hound to the ribosomes or proteins that bind mrna. Ribosomes, which are riboprotein complexes, bind mrna that is being actively translated in cells.
|Method and composition for crystallizing g protein-coupled receptors|
Certain embodiments provide a method for crystallizing a gpcr. The method may employ a fusion protein comprising: a) a first portion of a g-protein coupled receptor (gpcr), where the first portion comprises the tm1, tm2, tm3, tm4 and tm5 regions of the gpcr; b) a stable, folded protein insertion; and c) a second portion of the gpcr, where the second portion comprises the tm6 and tm7 regions of the gpcr..
|Modified polynucleotides for treating protein deficiency|
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmrna molecules.. .
|Cdc42 inhibitor and uses thereof|
Compounds which inhibit the small g protein rho gtpase cell division cycle protein cdc42 are provided. Morphological analyses of filopodia, western blots of ccd42 phosphorylation, and effects on cellular wound healing and on growth cone formation all demonstrate that the described compounds are able to inhibit all tested cdc42-mediated processes.
|Methods for treatment of nephrotic syndrome and related conditions|
The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein.
|Production of highly concentrated solutions of self-assembling proteins|
The present invention concerns stable aqueous protein dispersions comprising in an aqueous phase at least one self-assembling protein in dispersed form and also at least one specific dispersant for the self-assembling protein; processes for producing such stable aqueous dispersions; processes for electrospinning self-assembling proteins using such stable aqueous dispersions; processes for producing fibrous sheet bodies or fibers from such aqueous dispersions; the use of such aqueous dispersions for coating surfaces; the use of the materials produced by electrospinning in the manufacture of medical devices, hygiene articles and textiles; and also fibrous or fibrous sheet bodies produced by an electrospinning process of the present invention.. .
|Methods for cancer treatment using stem cells|
Various embodiments of the invention provide methods of treating cancer. Many embodiments provide methods of treating cancer using stem cells.
|Soluble proteins for use as therapeutics|
The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first single chain polypeptide comprising: (a) an antibody heavy chain sequence having vh, ch1, ch2, and ch3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the vh region; and (ii) a second single chain polypeptide comprising: (c) an antibody light chain sequence having a vl and cl region; and (d) a monovalent region of a mammalian binding molecule fused to the vl region; characterised in that each pair of vh and vl cdr sequences has specificity for an antigen, such that the total valency of said soluble protein is six.
|Methods for purifying insect membrane-bound receptor proteins from recombinant production hosts|
The invention is drawn to a method for purifying membrane-bound proteins expressed in recombinant insect cells using n-laurosarcosine. The invention is particularly suited for expressing cadherin-type receptors cloned from ostrinia nubilalis, european corn borer, and expressed in sf9 insect cells.
|Means and methods for mediating protein interference|
The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein.
|Proteases producing an altered immunogenic response and methods of making and using the same|
The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides dna molecules that encode novel variants, host cells comprising dna encoding novel variants, as well as methods for making proteins less allergenic.
|Selection of host cells expressing protein at high levels|
Provided is a dna molecule comprising a multicistronic transcription unit coding for i) a selectable marker polypeptide functional in a eukaryotic host cell, and for ii) a polypeptide of interest, the polypeptide of interest having a translation initiation sequence separate from that of the selectable marker polypeptide, wherein the coding sequence for the polypeptide of interest is downstream from the coding sequence for the selectable marker in the multicistronic transcription unit, and the nucleic acid sequence coding for the selectable marker polypeptide comprises a mutation that decreases the translation efficiency of the selectable marker in a eukaryotic host cell. Also provided are methods for obtaining host cells expressing a polypeptide of interest, the host cells comprising the described dna molecules.
|Biomarkers for myocardial ischemia|
This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) lumican and/or (ii) extracellular matrix protein 1 and/or (iii) carboxypeptidase n; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention..
|Cc2d2a gene mutations associated with joubert syndrome and diagnostic methods for identifying the same|
The present invention provides a method of screening a subject for mutations in the cc2d2a gene that are associated with joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with joubert syndrome including proteins that includes an amino acid sequence that terminates in dheggsgmes (seq id no: 1).
|Pregastric esterase and derivatives thereof|
The present invention relates to novel lipase polynucleotide sequences, their corresponding proteins as well as ways of manufacturing said sequences and said proteins and use of the proteins in the preparation of food compositions. The invention further relates to methods for releasing proteins from the exterior of a host cell as well as to a method for killing micro-organisms..
|Method for producing protein-carbohydrate vaccines reduced in free carbohydrate|
This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not.
|Vaccines and methods for using the same|
Improved anti-hiv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for hiv subtype a envelope protein, those having consensus sequences for hiv subtype b envelope protein, those having consensus sequences for hiv subtype c envelope protein, those having consensus sequences for hiv subtype d envelope protein, those having consensus sequences for hiv subtype b consensus nef-rev protein, and those having consensus sequences form hiv gag protein subtypes a, b, c and d.
|Prostaglandin e2 binding proteins and uses thereof|
The present invention encompasses prostaglandin e2 (pge2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, cdr grafted and humanized.
|Her3 antibodies binding to the beta-hairpin of her3|
The invention relates to anti-her3 antigen binding proteins, e.g. Anti-her3 antibodies, that bind to the beta-hairpin of her3, methods for selecting these antigen binding proteins, their preparation and use as medicament..
|Anti-her3/her4 antibodies binding to the beta-hairpin of her3 and the beta-hairpin of her4|
The invention relates to anti-her3/her4 antigen binding proteins, e.g. Anti-her3/her4 antibodies, that bind to the beta-hairpin of her3 and the beta-hairpin of her4, methods for selecting these antigen binding proteins, their preparation and use as medicament..
|Treatment of inflammatory diseases by inhibiting cold-inducible rna-binding protein (cirp)|
Disclosed are pharmaceutical compositions comprising a cirp inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a cirp inhibitor is also described herein..
|Method of manufacturing protein semiconductor, protein semiconductor, method of manufacturing pn junction, pn junction, method of manufacturing semiconductor apparatus, semiconductor apparatus, electronic apparatus, and method of controlling conductivity type of protein semiconductor|
A conductivity type of a protein semiconductor is controlled by controlling total amount of charge in amino acid residues, a p-type protein semiconductor or an n-type protein semiconductor is manufactured, and a pn junction is manufactured using the p-type protein semiconductor and the n-type protein semiconductor. The total amount of charge in amino acid residues is controlled by substituting one or more of an acidic amino acid residue, a basic amino acid residue, and a neutral amino acid residue, which are contained in protein, with an amino acid residue having different properties, chemically modifying one or more of an acidic amino acid residue, a basic amino acid residue, and a neutral amino acid residue, which are contained in the protein, or controlling polarity of a medium surrounding the protein..
|Combinations of cry1ab and cry1fa as an insect resistance management tool|
Compositions for controlling lepidopteran insects use cry1fa and cry1ab core toxin containing proteins in combination to delay or prevent development of resistance.. .
|Plants having enhanced yield-related traits and a method for making the same|
The present invention relates generally to the field of molecular biology and concerns a method for enhancing various economically important yield-related traits in plants. More specifically, the present invention concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a yield enhancing protein (yep).
|Methods using acyl-coenzyme a-binding proteins to enchance drought tolerance in genetically modified plants|
Acbp2 can be used to enhance drought tolerance in genetically modified plants. Acbp2 was observed to be expressed in guard cells, and acbp2-overexpressing transgenic arabidopsis were conferred enhanced drought tolerance.
|Sperm cell separation methods and compositions containing sperm cell targeting ligands for use therein|
The present invention provides sperm cell targeting ligands, including dna-binding proteins, that bind target molecules on the surface of, accessible from the surface of, or inside mammalian sperm cells and methods for producing the sperm cell targeting ligands. The sperm cell targeting ligands are used to separate sperm cells based upon sperm cell qualities, such as whether the cells contain x chromosomes or y chromosomes.
|Protein purification using hcic and ion exchange chromatography|
The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step..
|Methods of inhibiting protein tyrosine kinase activity|
This invention relates to methods for inhibiting kinase activity and/or inhibiting angiogenesis and/or treating a disease responsive to inhibition of kinase activity and/or treating a cell proliferative disease and/or treating an ophthalmic disease, condition or disorder treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions comprising administering novel compounds that inhibit protein tyrosine kinase activity.. .
|Methods for the selection of binding proteins|
This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mrna display and yeast surface display in a way that takes advantage of the desirable attributes of both processes..
|Modifying proteins (gpcr), ligands, and nanopore surfaces to allow the detection of create binding-induced molecular changes of protein-ligand complexes with nanochannel translocation|
A mechanism is provided for utilizing a nanodevice to distinguish molecules with different structure. The molecules translocate through or across a nanochannel filled with a electrolyte solution.